4-Aminopyridine (4-AP) is a K+ channel blocking agent that enhances nerve conduction through areas of demyelination by prolonging the duration of the action potential and increasing the safety factor for conduction. We have investigated the effects of 4-AP (24 mg total dose-intravenous) in 6 patients with spinal cord injury (3 complete, 3 incomplete) with the intent of overcoming central conduction block, or slowing, due to demyelination. Vital signs remained stable and only mild side effects were noted. The 3 patients with incomplete injuries all demonstrated enhanced volitional EMG interference patterns and one patient exhibited restored toe movements. The changes were reversed on drug washout. There were no changes in segmental reflex activities. These results are consistent with those obtained from 4-AP trials with animal models of spinal cord injury, showing modest therapeutic benefit attributable to enhanced central conduction.
Introduction
Conduction deficits due to demyelination of axons within the spinal cord are now recognized to constItute a significant component of the pathology of spinal cord injury (SCI).1 -7 As a corollary, restoration of conduction in demyelinated fibres has been identified as an important strategy for promoting functional recovery in SCI pa tients with compressive or contusion in juries. 8 4-Aminopyridine (4-AP) is a potassium (K + ) channel blocking agent that has the capability to pass through the blood brain barrier,9 overcome conduction block in demyelinated neurons,1 0-1 3 improve the neurological function of various animal models of SCI,1 4, 15 and improve clinical signs in temperature-sensitive patients with multiple sclerosis.1 6 .17.1 8 4-AP has not previously been administered to patients with SCI . , al � hough it �a � under�on � wides ,g read testmg III other chmcal apphcatiOns 1 9-d and there is adequate knowledge of its pharmacokinetics. 24-2 7 The pharmacological action of 4-AP in demyelinated or dysmye linated neurons is to prolong the duration of the action potential, by blocking the vol tage-sensitive 'fast' K + channels, thereby increasing the safety factor for conduc tion. 11 . 2 The present open trial of intravenously administered 4-AP in chronic SCI patients was undertaken (a) to identify any side effects of the drug and (b) to provide preliminary observations of the efficacy of the drug in enhancing sensory and motor function. In addition to recording clinical, functional and electrophysiological indices of sensori-motor status, careful monitoring was undertaken of vital signs and electro encephalograms (EEG) as well as video recording of any restored movement capab ility.
Methods

Subjects
Six volunteer male SCI patients provided informed consent to participate in the trial. A seventh patient started the trial but his participation was discontinued when un successful venipuncture resulted in the first dose of 4-AP inducing a local vasoconstric tion with blanching and cooling of the forearm. The mean age of the group was 29.5 years, and all had experienced trau matic lesions as a consequence of motor vehicle accidents. All were able to discon tinue their medications for sufficient time to allow drug washout prior to the 4-AP trial. Three of the patients presented with clinic ally complete injuries and three were incom plete. Their clinical characteristics are re ported in Table I . The inclusion criteria were: traumatic paraparesis, paraplegia, quadriparesis or quadriplegia, neurological level of injury C5-T12, medically stable, aged 18-50 years, and with acknowledge ment by their physician of participation. Excluded were patients with brain damage or neuropsychological deficits, including posttraumatic amnesia with a Galveston orientation and amnesia test score less than 76; family or personal history of epilepsy or other seizure disorders; known cardiovascu lar, metabolic, kidney or respiratory abnor malities; allergy to pyridine-containing medications; excessive pain or spasticity; or nicotine dependence. was assessed using tibial nerve SEPs (3.1 Hz stimulation with Cz-Fz recording), or in 2 cases using median nerve stimulation with C 3 -Fz recording, and voluntary contraction EMG interference patterns were recorded from tibialis anterior (TA), lateral gastro cnemius (L G) and rectus femoris (RF) muscles. In addition, central motor conduc tion was evaluated by motor evoked poten tials (MEPs), elicited using transcranial magnetic stimulation of motor cortex, and reinforced with target and remote muscle contraction. 3 6 ,37 Cortical stimulation was delivered from a Cadwell MES-I0 magnetic stimulator through a 9 cm focal point coil electrode with posterior rim over vertex. 33, 37 The central motor conduction tests were only recorded prior to drug adminstration because of the potential combined risk of both 4-AP and cortical stimulation lowering seizure threshold.
Vital signs Oral temperature, systolic and diastolic blood pressure, respiratory rate and electro cardiogram (ECG) were monitored period ically throughout the testing by a nurse and emergency medicine physician. EEG re cordings were made continuously using a Grass model 8-10D electroencephalograph with 8 channel montage.
Urinalysis for 4-AP
Detection of urinary concentration of 4-AP was done using a Hewlett Packard 1090 HPLC with UV @ 254 nm. Urine samples were diluted 1: 11 (100 fLI in 1.0 ml MeOH) and injected directly onto the column (15 cm x 4.6 mm 1 D Beckman Ultrasphere 1 P.C18, 5 u). The retention time was 3.5 min. Since no extraction was used and injections were automated no internal standard was used. The coefficient of vari ation for quality control samples (1000 fLgL -1) was 3.7% .
Results
All 6 patients tolerated the drug admin istration well and without significant side effects (see below). The investigations lasted approximately 6 hours from the be ginning of pre-drug testing, through 4 hours of drug administration and 2 hours post drug tests. Most patients spontaneously reported fatigue at the end of the testing.
Vital signs
During administration of 4-AP the group mean oral temperature, systolic and dia stolic blood pressure, respiratory rate and heart rate did not differ significantly from the baseline values (Table II) . There were no obvious changes in the ECG. EEG recordings typically showed normal baseline EEG consisting of alpha and some beta activity and in one subject there was evid ence of a decrease in amplitude of alpha activity associated with subjective reports of ligh theadedness after � 14 mg 4-AP. It is not entirely clear whether the lightheadedness was due to the drug, fasting, or other factors, although Stefoski et al16 have also Pre drug refers to immediately prior to first 2 mg dose of 4-AP.
Post drug refers to 20 min after last 2 mg dose of 4-AP.
All measurements based on n = 6 and SD refers to the between-patient standard deviation.
reported lightheadedness during adminstra tion of 4-AP. The episode passed quickly and the subject continued to receive the total dose (24 mg). During administration of 4-AP each one of the 3 patients with incomplete motor loss (1, 2 and 5) showed enhanced volitional motor unit recruitment and EMG interfer ence patterns. The time course of changes varied appreciably across patients. Patient 5 revealed a progressive enhancement of motor unit recruitment in T A. This was even more striking when the contractions were reinforced by lendrassik's maneuver (Fig 2) . The enhancement of volitional motor unit recruitment was in a muscle that in pre-drug testing was electrically quies cent, but which revealed MEPs following cortical stimulation reinforced with at tempted target muscle contraction (Fig 1) . The patient also reported restored capabil ity to move the fourth and fifth toes of his right foot which he could not do prior to receiving 4-AP. The restored flexion/exten- 
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Lat. Gast. Tib. Ant. sion movements were lost on drug washout. Video analysis verified the changes in move ment capability. Patients 1 and 2 both revealed increased amplitude and density of EMG interference patterns during maximal voluntary contrac tions in TA or RF after 12-16 mg 4-AP, but this enhancement appeared to lessen during the final stages of drug administration (20-24 mg) . Associated contractions in the contralateral leg reduced in intensity (ie reduced amplitude and density of EMG interference patterns) as the strength of the ipsilateral leg contractions increased. There were no appreciable changes in the motor index scores or Frankel class ratings of any patients.
Segmental reflexes
In all patients from whom posterior tibial nerve H-reflexes and M-waves could be recorded (n = 5), the amplitude and latency of posterior tibial nerve H-reflexes and the amplitude of M-waves generally remained constant during or after adminstration of 4-AP (Table III) . Analysis of variance, with Bonferroni post hoc tests, revealed a consistent reduction in M-wave latency ( p < .05) at all levels of drug adminstered, compared to the pre-drug value. Since the change did not appear to be dose depend ent, and was not accompanied by commen surate changes in H-reflex latency, or 4-AP in spinal cord injury 221 M-wave amplitude, we interpret this effect to be artifactual. There were indications of a reduced amplitude of the H-reflex after 8 mg 4-AP but this was not significant (p> .05). Similarly there was a reduction in flexion reflex amplitude and elevated stimu lation threshold in some patients after 8 mg 4-AP, but this was not consistent across patients. There were no clear indications of any individual patients showing altered seg mental reflex activity. Particular attention was focused on the segmental reflex proper ties of patient 3 who had a surgically verified anatomically complete severance of the cord at T3. This 'spinal' man provided an oppor tunity for detailed examination of any peri pheral effects of 4-AP, eg on neuro neuronal transmission in the isolated cord or neuromuscular transmission. No consistent changes were observed in the latency or amplitudc of his H-reflexes, M-waves, or polysynaptic flexion reflexes evoked by cu taneous stimulation in the lower limbs.
Side effects
All patients complained of localized mild to moderate discomfort around the insertion site of the intravenous line. Two patients exhibited behaviours associated with mild perioral paraesthesia and one reported a transient period of lightheadedness at 12 mg 4-AP associated with periodic low am plitude EEG activity. There were no other All measures based on n = 5. Posterior tibial nerve H-reflex and M-waves were not recorded from one patient who had an L4 vertebral fracture in addition to a thoracic level neurological lesion.
*The M-wave latency at each level of drug administration was significantly (p < .05) reduced from the pre-drug value.
side effects apart from a generalized fatigue and some mild irritability, associated with the prolonged duration of intense investiga tion.
Urinary excretion
The urinary excretion profiles exhibited considerable variability in 4-AP concentra tion levels, among patients. They showed a large peak urinary concentration of 4-AP occurring 2-3 hours after the start of drug administration (16-20 mg). There was also some evidence of a second late peak (2969 IlgL -1 ) occurring 10 hours after the initial dose in one quadriplegic patient (6) . The sparse intermittent sampling precluded careful delineation of the time course of either the first of second peak. By the following morning the urinary concentration of 4-AP was reduced to close to zero flgL -1 in all patients.
Discussion
This open, preclinical trial of intravenous 4-aminopyridine was undertaken to identify any adverse side effects when delivered to SCI patients, and to document any enhance ment in sensory or motor status. The side effects observed in the present trial, of localized forearm discomfort, mild perioral paraesthesia, and, in one subject, transient lightheadedness, were anticipated and have all been noted before. 1 6 -22 None was sufficient for the patients to discontinue the trial. The small number and the mild ness of the side effects noted were most likely related to the conservative total dose of 24 mg (which corresponded to -0.3 mg' kg-I) and the rate of delivery (over 3.6 hours). Elsewhere there have been reports of paraesthesia, giddiness, ataxia, agitation and even epileptiform seizure activity when appreciably higher doses of 4-AP have been administered and at faster rates. 1 6-22 . 2 4,38 The present observations indicate that with a conservative total dose and rate of de livery, and with rigorous criteria applied to the selection of patients, 4-AP appears safe to administer to SCI patients.
Urinary excretion profiles were generally consistent with previously reported results, Paraplegia 31 (1993) [216] [217] [218] [219] [220] [221] [222] [223] [224] although the appearance of a second peak in 4-AP urinary concentration (-2969 flgL -1 ) as late as 6 hours after the final 2 mg dose in one quadriplegic patient was not expected. Secondary peaks in 4-AP plasma concentra tion levels at 20-60 min have been noted previously and attributed to entero-systemic recirculation. 27 The prolonged excretion profile may simply reflect normal variability or may indicate some pathophysiological change such as reduced renal perfusion with lowered renal clearance rate. There is little or no biotransformation of 4-AP in man.
There was no electrophysiologic evidence of any sensory changes, although one pa tient reported qualitative changes in re sponse to pinprick. Enhancement of visual evoked potentials (with enhanced visual acuity) by 4-AP has been reported in tem perature sensitive multiple sclerosis (MS) patients. 1 6-1 8
All 3 patients with incomplete injuries exhibited enhanced volitional motor unit activity during the administration of the drug. In one patient, this improvement was reflected in the de novo voluntary activation of motor units. This improvement was sustained throughout the course of delivery of the drug and appeared dose dependent. The enhanced volitional effort was also manifest in restored toe flexion and exten sion; a movement capability that reversed after 24 hours when the drug had been eliminated. In the other 2 patients the increase in amplitude and density of volun tary effort EMG interference patterns reached a maximum at 12-16 mg 4-AP but diminished with further increments in the drug.
Davis et al l7 have reported maximal therapeutic benefit of 4-AP in MS patients at doses of 12-14 mg, and noted declining motor function at higher doses using the same rate of delivery as the present study. 1 8 This has been attributed to the inadequate summation of drug effects, given the ac knowledged short half life of 4-AP (-4 hours)25.27 and the considerable between patient variability that exists in plasma concentration and urinary excretion rates25,27 (Stefoski, personal communica tion). A similar interpretation would apply to our observations in SCI patients if pa-tients (1 and 2) had relatively short half life for 4-AP availability. The urinary excretion data obtained from patients 1 and 2 are consistent with this interpretation, but not definitive by virtue of sparse sampling.
The observation that there were no changes in segmental reflex excitability, particularly in the patient (3) with surgically verified complete disruption of his cord, suggests that the observed changes in motor function in patients 1, 2 and 5 could be attributable to enhanced central conduc tion. 4-AP induced alterations in neuro neuronal and neuromuscular transmission are known to occur, 2 6 but these effects are typically evident at higher dose levels, or higher rates of delivery than those used in the present study. Conduction failure due to demyelination has been shown to be over come by 4-AP in various in vitro prepara tions 1 3 and has been assumed to underlie the improvements in clinical signs in MS 16 -1 X and the improved function in animal models of SCI. 14 . 15 The relatively modest changes in electro physiological indices of motor function seen with 4-AP in the present study may be attributable to the conservative rate of drug administration (relative to its half life). Alternatively, the patients who volunteered may have had injuries principally involving axonal damage, as distinct from demyelina tion or dysmyelination. In order to assist with future identification of patients most likely to benefit from 4-AP or other K+ channel blocking agents, a test has now been developed for revealing temperature sensitive central conduction deficits.39 With either induced hypothermia or with 4-AP, procedures which both prolong the duration of the action potential, there is an increase in the safety factor for conduction,3 0 and in both instances there has been tangible evid ence of enhanced conduction and restored voluntary motor function in SCI patients. 39 The principle of attempting to manage conduction failure due to demyelination in SCI patients thus appears to be promising and to warrant continued study.
